NewGenIvf Appoints New Auditor for FY2024

TL;DR

NewGenIvf swapped auditors for 2024, effective Sept 3rd.

AI Summary

NewGenIvf Group Limited announced on September 3, 2024, the appointment of J&S Associate as its independent registered public accounting firm for the fiscal year ending December 31, 2024. This appointment follows the termination of services from the previous accounting firm.

Why It Matters

Changing auditors can signal a shift in financial reporting scrutiny or a response to previous audit findings, potentially impacting investor confidence.

Risk Assessment

Risk Level: low — The filing is a routine change of auditor announcement with no immediate financial implications.

Key Players & Entities

• NewGenIvf Group Limited (company) — Registrant
• J&S Associate (company) — Newly appointed independent registered public accounting firm
• September 3, 2024 (date) — Effective date of auditor appointment
• December 31, 2024 (date) — Fiscal year end for which the auditor is appointed

FAQ

Filing Documents

• ea0213191-6k_newgen.htm (6-K) — 11KB
• 0001213900-24-075321.txt ( ) — 12KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-42004 NEWGENIVF GROUP LIMITED (Translation of registrant’s name into English) 36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district Watthana District, Bangkok 10110 Thailand (Address of Principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Effective on September 3, 2024, Newgenivf Group Limited (the “Registrant”) has appointed J&S Associate (“J&S”) as its independent registered public accounting firm for the fiscal year ending December 31, 2024. The Registrant has terminated the services of the Registrant’s previous independent auditor, Onestop Assurance PAC (“Onestop”) effective on September 3, 2024. The termination of Onestop and the appointment of J&S was made after careful consideration and evaluation by the Registrant and has been approved by the Audit Committee and the Board of Directors of the Registrant. During the Registrant’s two most recent fiscal years ended December 31, 2023 and 2022, through the termination of services of Onestop on September 3, 2024, there were no disagreements between the Registrant and Onestop on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Onestop, would have caused it to make reference to the subject matter of the disagreements in connection with its report on the Registrant’s consolidated financial statements for such periods. In addition, Onestop’s reports on the financial statements as of and for the fiscal year ended December 31, 2023 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal year ended December 31, 2023 through the termination of services of Onestop on September 3, 2024, there were no “reportable events” as that term is defined in Item 16F(a)(1)(v) of Form 20-F. During the two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period prior to engaging J&S, neither the Registrant nor anyone on its behalf consulted J&S regarding either (i) the application of accounting principles to any proposed or completed transaction, or the type of audit opinion that might be rendered on the Registrant’s financial statements, and neither a written report nor oral advice was provided to the Registrant that J&S concluded was an important factor considered by the Registrant in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions to Item 16F of Form 20-F) or a reportable event. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 4, 2024 NewGenIvf Group Limited By: /s/ Wing Fung Alfred Siu Name: Wing Fung Alfred Siu Title: Chairman of the Board and Director 2

View Full Filing

View this 6-K filing on SEC EDGAR